5.71 USD
↗ 0.00 (0.00%)AT CLOSE (11:59 AM EDT)
Aligos Therapeutics, Inc. Common Stock
ALGSNASDAQ • USD
5.85
↗ 0.14 (2.45%)
POST MARKET (AS OF 07:47 PM EDT)
Post Market
AS OF 07:47 PM EDT
5.85
↗ 0.14 (2.45%)
Market: CLOSED
Open?$6.49
High?$6.66
Low?$5.68
Prev. Close?$5.71
Volume?179.3K
Avg. Volume?346.9K
VWAP?$6.01
Rel. Volume?0.52x
Bid / Ask
Bid?$5.78 × 200
Ask?$6.02 × 100
Spread?$0.24
Midpoint?$5.90
Valuation & Ratios
Market Cap?35.3M
Shares Out?5.4M
Float?4.6M
Float %?75.5%
P/E Ratio?N/A
P/B Ratio?1.11
EPS?-$14.60
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Themes
Employees
82
Market Cap
35.3M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2020-10-16
Address
ONE CORPORATE DR., 2ND FLOOR
SOUTH SAN FRANCISCO, CA 94080
Phone: (800) 466-6059
SOUTH SAN FRANCISCO, CA 94080
Phone: (800) 466-6059
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?2.55Strong
Quick Ratio?2.55Strong
Cash Ratio?1.29Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUED
Score83/100
P/E?N/A▾
P/B?1.11CHEAP▾
P/S?7.51HIGH▾
P/FCF?N/A▾
EV/EBITDA?-0.1CHEAP▾
EV/Sales?1.16CHEAP▾
Returns & Efficiency
ROE?-284.1%WEAK▾
ROA?-139.9%WEAK▾
Cash Flow & Enterprise
FCF?$-85185000
Enterprise Value?$5.4M
Fundamentals ratios updated end of day